Adverum Biotechnologies (ADVM) has been on a downward spiral lately with significant selling pressure. After declining 19.7% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whet ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________________________________________________ FORM 10-Q ___________________________________________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☒ EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 For the transition period from to Com ...

Exhibit 99.1 Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights - Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 - REDWOOD CITY, Calif., May 9, 2024 - Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standar ...

REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences: 2024 RBC Global Healthcare Conference on Tuesday, May 14, 2024 at 4:05 p.m. ET.BofA Securities 2024 Health Care Conference on Wednesday, May 16, 2024 at 3:40 p.m. PT.H.C. Wainwright 2nd Annual B ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Adverum Biotechnologies (ADVM) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Adverum Biotechnologies is one of 1051 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different g ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adverum Biotechnologies (ADVM) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Adverum Biotechnologies is one of 1054 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank inc ...

ADVM股票表现 - ADVM 是一个值得投资者关注的股票[1] - ADVM 所在的医疗 - 生物医学和遗传学领域正在经历强劲的盈利预期修订活动[1] - ADVM 的盈利预期修订活动表现良好，分析师对公司未来前景持乐观态度[3] ADVM盈利预期修订 - 过去一个月，ADVM 的当季盈利预期从每股亏损3.30美元缩小至每股亏损1.30美元，当年盈利预期从每股亏损7.73美元缩小至每股亏损5.18美元[4] - ADVM 获得了Zacks Rank 2 (Buy)的评级，进一步突显了公司的稳健地位[4] ADVM行业地位 - ADVM 所在的行业处于前三分之一的位置，近期盈利预期修订良好，对于寻找这一优秀行业领域的投资者来说，可能是一个非常有趣的选择[5]

ADVM股票走势分析 - Adverum Biotechnologies (ADVM) 最近呈现出明显的下降趋势，受到过多的卖压影响[1] - RSI是一种常用的技术指标，用于判断股票是否被卖过头[2] - RSI在0到100之间波动，通常当股票的RSI指标低于30时被认为是被卖过头[3] - RSI有助于快速检查股票价格是否即将出现反转[4] - ADVM股票的RSI指标为25.4，显示卖压正在逐渐消耗，股票的趋势可能很快会出现反转[7] - 分析师们普遍认为ADVM有望报告比他们之前预测的更好的收益，这也是股票可能出现反弹的原因之一[8] - ADVM目前拥有Zacks Rank 2（买入），这意味着它在我们根据盈利预期修订和EPS惊喜趋势对超过4000支股票进行排名中处于前20%[9]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adverum Biotechnologies (ADVM) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Adverum Biotechnologies is a member of the Medical sector. This group includes 1063 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank ...

公司概况 - Adverum是一家临床阶段公司，旨在将基因疗法确立为高患病率眼部疾病的新标准[34] - 公司的战略是发现、开发和商业化新型基因疗法，以治疗患有高发性眼部疾病的患者[47] - 公司的目标是发现、开发和商业化具有潜力治疗患有高发性眼部疾病的患者的新型基因疗法[47] 资金情况 - 我们预计现金、现金等价物和短期投资将足以支持计划到2025年底的运营[12] - 我们将需要筹集额外资金，这些资金可能无法以可接受的条件获得，甚至根本无法获得[13] 业务风险 - 我们的业务将在很大程度上取决于一个或多个产品候选药物的成功。如果我们无法开发、获得监管批准或成功商业化任何一个或所有的产品候选药物，我们的业务将受到重大损害[14] - 药物开发是一个漫长、昂贵且不确定的过程，延误或失败可能发生在任何阶段，包括在我们的临床试验或使用我们专有病毒载体的任何临床试验开始后[15] - 我们的成功取决于我们保护我们的知识产权和专有技术的能力[22] - 我们将依赖第三方在合同和合作伙伴关系下进行我们研究和开发的某些或所有方面，这些第三方可能无法令人满意地执行[20] - 我们将依赖第三方进行一些非临床测试和我们计划的所有临床试验。如果这些第三方未能按照要求进行试验，我们的临床开发计划可能会延迟或失败，我们可能无法按预期或根本无法获得监管批准或商业化我们的产品候选药物[21] - 公司的股票交易价格一直可能会高度波动，购买我们的普通股的投资者可能会遭受重大损失[32] 产品信息 - Ixo-vec是公司的主要产品候选人，旨在通过单次办公室内视网膜注射基因疗法，提供持久的疗效，降低治疗负担和视网膜液体波动[35] - Ixo-vec获得FDA的快速通道、EMA的PRIME和MHRA的创新护照[43] - 公司的Ixo-vec基因疗法产品候选品针对湿性AMD，采用专有载体，通过单次IVT注射给药，将与当前市场上已上市和正在研发的各种疗法竞争，包括生物制剂、小分子药物、长效给药装置和基因疗法[117] - Ixo-vec是Adverum的主要基因治疗产品候选药物，旨在治疗患有湿性AMD的患者，通过单次IVT注射提供长期、持久的治疗效果[67] - Ixo-vec的OPTIC临床试验显示，患者在接受Ixo-vec后，抗VEGF注射次数显著减少，保持视力和黄斑厚度，且耐受性良好[84] - Ixo-vec的三年数据显示，接受6E11剂量的患者抗VEGF注射减少98%，接受2E11剂量的患者抗VEGF注射减少84%，并保持视力和黄斑厚度[85] - Ozurdex加difluprednate眼药水可能是未来关键研究的有前途的预防方案[42] - Wet AMD是一种进行性疾病，影响视网膜细胞，导致逐渐失明，全球约有2000万人患有湿性AMD[70] - Wet AMD的标准治疗需要频繁的抗VEGF注射，但患者遵循治疗计划的困难导致持续性黄斑液体和视力丧失[72] - Wet AMD是一种导致65岁以上患者失明的主要原因，全球患病人数约为2000万人，预计到2040年，全球AMD患者将达到2.88亿人，其中湿性AMD约占10%[37] - OPTIC试验显示，Ixo-vec在6E11和2E11剂量下表现出强烈的治疗效果信号，包括最佳矫正视力和中央视野厚度的维持和改善，以及稳定的aflibercept蛋白水平[39] - LUNA Phase 2试验初步安全和有效性数据显示，2E11和6E10剂量均表现出维持视觉和解剖结果，减少抗VEGF注射频率[41] 市场竞争 - 美国大多数患者接受非标签使用的bevacizumab，包括作为一线治疗。许多患者随后接受Eylea、Eylea HD和Vabysmo®（faricimab）。目前有许多针对慢性视网膜疾病的产品候选品正在开发或最近获批，这些产品对抗VEGF疗法产生反应，包括湿性AMD[118] - 公司面临着来自美国和欧洲的其他公司的竞争，这些公司已经上市产品或正在开发针对对抗VEGF疗法产生反应的慢性视网膜疾病的产品，包括湿性AMD[119] - 公司可能面临来自其他竞争对手的激烈和不断增加的竞争，随着新药物进入市场和先进技术的出现，我们预计我们开发和商业化的任何治疗方法将在疗效、安全性、给药和递送便利性、价格、通用竞争水平和政府及其他第三方支付者的报销可用性等方面展开竞争[121] 监管法规 - 美国生物产品主要受联邦食品、药品和化妆品法案（FD&C法案）和公共卫生服务法案（PHS法案）管辖[142] - 在美国，生物产品的监管由生物制品评估和研究中心（CBER）负责[143] - 在美国市场推出产品需要完成一系列步骤，包